 "Torrent pharma")
To commercialize Vonoprazan in India Torrent Pharmaceuticals (Torrent) today announced that it has entered into a non-exclusive patent licensing agreement with Takeda to commercialize Vonoprazan in India. Vonoprozan is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of acid related disorders - Gastroesophageal Reflux Disease (GERD). Torrent will market Vonoprazan under its own trademark, Kabvie.
As per a 2019 study published by Indian Journal of Gastroenterology prevalence of GERD in Indian population is around 8.2 per cent, with a higher prevalence of around 11.1 per cent in urban population. According to AWACS MAT April 2024 data, the Indian market for treatments used in GERD is valued at INR 8,064 crore, growing at 8 per cent CAGR over the last 4 years. Currently treatments such as Pantoprazole (Proton Pump Inhibitors) are used to treat GERD. Availability of P-CABs such as Kabvie will make accessible new and effective treatments of GERD for the Indian population.
Powered by Capital Market - Live News
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
